Summary: Researchers demonstrated that a ketogenic diet, which shifts the body away from glucose and toward fat-derived ketones for fuel, induces rapid metabolic improvements and alleviates persistent psychiatric symptoms.
By bypassing defective glucose pathways, this metabolic psychiatry intervention successfully restored energy to the brain, driving meaningful gains across metabolic, cognitive, and psychological measures without any significant side effects.
Key Facts
- The High Ketosis Feasibility: A common criticism of nutritional psychiatry is that restricted diets are too difficult for patients with severe mental illness to sustain. This trial shattered that assumption, reporting an 83% compliance rate in maintaining ketosis during the one-month phase, which rose to a striking 94% during the four-month extension, with zero reports of severe side effects.
- The Controlled Ketone Factor: During the first month, participants on the ketogenic diet showed massive metabolic improvements compared to the diet-as-usual control group. Crucially, higher circulating blood ketone levels directly correlated with sharp drops in blood glucose and a significant reduction in depression symptoms.
- Ketosis vs. Weight Loss: The psychiatric relief remained highly pronounced even after researchers mathematically accounted for weight loss. This proves that the state of nutritional ketosis itself, supplying the brain with an alternative, highly efficient fuel source, drives the therapeutic mental health benefits, rather than basic weight reduction.
- The Four-Month Cognitive Gains: While a one-month dietary shift was enough to correct metabolic issues, the real psychological breakthrough required time. Participants who completed the optional four-month extension saw sustained reductions in both clinical depression and core schizophrenia symptoms, alongside marked improvements in daily cognitive performance.
- Addressing Medication Blind Spots: Standard antipsychotics leave patients feeling cognitively blunted and exhausted. Lead author Judith M. Ford emphasizes that seeing measurable cognitive and psychological improvements is highly important, as current medications entirely fail to address these debilitating lifestyle symptoms.
- A Call for Public Investment: Jan Ellison Baszucki, president of the Baszucki Group, notes that this study adds to a growing wave of clinical pilot trials validating metabolic psychiatry. The authors call for large-scale, extended clinical trials to establish standardized, brain-centric nutritional therapies across public healthcare platforms.
Source: Stellate Communications
Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders.
The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase.
Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures.
Of the 58 participants enrolled, 47 completed the initial comparison between a one-month ketogenic diet intervention and a diet-as-usual control group. Twenty-five participants opted to continue the intervention for a total of four months, in a single-arm extension.
The study showed high feasibility, with 83% of daily-tested participants maintaining ketosis in the one-month RCT portion and 94% in the four-month extension, with no reports of significant side effects from the diet.
After one month on the ketogenic diet, participants showed statistically significant improvements in key metabolic markers compared with the control group. In this controlled trial, higher ketone levels were associated with reductions in blood glucose and lower depression symptoms (PHQ-9), even after accounting for weight loss, suggesting that ketosis itself, rather than weight reduction alone, may play a role in the observed effects.
The four-month extension demonstrated that metabolic improvements were sustained alongside significant reductions in depression and schizophrenia symptoms, as well as enhanced cognitive performance. While this was a 25-participant single-arm extension, it represents an encouraging signal that the ketogenic diet is a potential intervention for serious mental illness.
“The improvement we saw in cognitive and psychological symptoms is particularly important in people with psychotic disorders, because current medications that address their psychosis don’t address their overall mental wellbeing, including cognitive or depressive symptoms, which can be debilitating,” said study lead Judith M. Ford, PhD, Professor of Psychiatry at UCSF and the Weill Institute for Neurosciences. Dr. Ford noted that while the findings are encouraging, they underscore the need for larger, longer, fully controlled trials to establish whether these benefits hold up at scale.
The authors emphasize that a one-month intervention appears insufficient to capture the potential therapeutic mental health benefits of the intervention, and that the significant cognitive and psychiatric improvements seen at four months need to be replicated under controlled conditions.
These results align with recent pilot studies in schizophrenia and bipolar disorder, and together indicate the need for larger, extended randomized controlled trials to test the efficacy and safety of ketogenic therapy in patients with serious mental illness.
“This study reinforces the evidence that ketogenic therapy is a feasible, safe, and potentially transformative treatment for serious mental illness,” said Jan Ellison Baszucki, co-founder and president of Baszucki Group, who was among the funders of the study. “Now is the time for diverse and sustained investment in rigorous scientific examination of metabolic approaches to psychiatry to expand the scope of these studies and to raise awareness for its potential.”
Key Questions Answered:
A: Emerging research suggests that serious psychiatric disorders are deeply tied to a biological issue called “cerebral hypometabolism”, essentially, a defect where the brain struggles to properly process glucose for energy, leaving its cells starved and unstable. When a patient switches to a ketogenic diet, the liver converts fat into alternative energy units called ketones. These ketones easily bypass the brain’s broken glucose engines, providing a highly efficient, steady fuel source that stabilizes brain cell networks and reduces the underlying biological drivers of psychiatric distress.
A: Surprisingly, no. While a ketogenic diet naturally leads to weight reduction, the UCSF research team specifically isolated this variable in their mathematical models. They discovered that higher blood ketone levels directly predicted a reduction in severe depression symptoms even after fully adjusting for weight loss. This proves that the neurological benefits are driven by the chemical state of ketosis itself—the direct presence of alternative ketone fuel in the brain, rather than the passive physical benefits of shedding pounds.
A: While this study demonstrated incredible safety and an amazing 94% adherence rate, it is vital to remember that this trial was conducted under close clinical supervision. Patients with serious mental illness are often taking complex medications that interact directly with their metabolism. Dr. Judith M. Ford and the research team stress that while the ketogenic diet is a highly promising, transformative treatment tool, it should always be initiated and tracked in partnership with a qualified psychiatrist and medical professional to ensure safety and stability.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this psychology and diet research news
Author: Clare Reynell
Source: Stellate Communications
Contact: Clare Reynell – Stellate Communications
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Metabolic improvements with a ketogenic diet correlate with symptom improvement in psychosis: A randomized controlled trial” by An Vu, Daniel H. Mathalon, Judith M. Ford, Juliette M. Kyner, Michael S. Jacob, Samantha V. Abram, Shebani Sethi, Susanna L. Fryer, Zanib Naeem. Schizophrenia Bulletin
DOI:10.1093/schbul/sbag082
Abstract
Metabolic improvements with a ketogenic diet correlate with symptom improvement in psychosis: A randomized controlled trial
Background and Hypothesis
Psychiatric medications contribute to high rates of metabolic dysfunction in psychotic disorders. Ketogenic diets reduce metabolic syndrome, have anticonvulsant effects in epilepsy, and may improve symptoms of schizophrenia and bipolar disorder. We report the first randomized controlled trial to assess effects of ketogenic diets on metabolism, psychiatric symptoms, and cognition in people with schizophrenia-spectrum and bipolar-1 disorders.
Study Methods
Participants were randomized to a ketogenic diet (KETO; n = 28) or diet-as-usual (DAU; n = 30) for 1 month. Partway through the trial, a KETO extension was offered to both groups, resulting in a sub-group who completed the diet for 4 months (n = 25). We assessed changes in metabolic health, clinical symptoms, and cognition after 1 month (KETO versus DAU) and after 4 months (KETO versus baseline).
Study Results
KETO participants’ daily ketone levels surpassed the standard ketosis threshold. Relative to DAU, KETO participants showed reductions in weight (Padj < .001), hemoglobin A1c (Padj = .05), and insulin resistance (Padj = .05). Clinical symptoms (positive, negative, depression) and cognitive performance improved after 4 months on the KETO (all P-values < .001). Increased blood ketone levels in KETO participants correlated with improvements in pre-diabetic markers and depressive symptoms (all P-values < .001). Reduced weight following the KETO was unrelated to metabolic and symptom improvements.
Conclusions
We demonstrate feasibility of administering a KETO in outpatients with schizophrenia and bipolar-1 disorder. Participants showed improvement in metabolic health, cognitive performance, and clinical symptoms. Improvement in depressive symptoms was associated with ketosis rather than weight loss, implicating ketosis as the therapeutic mechanism.
